https://www.statnews.com/2023/10/31/eli-lilly-beam-stake-in-gene-editing-firm-verve/
Eli Lilly said it will pay $200 million cash to gene-editing firm Beam Therapeutics for Beam’s stake in Verve Therapeutics, another gene-editing company focused on treatments for heart disease.
Create an account
or login to join the discussion